Can DIO1 rs2235544 variants change T4-to-T3 conversion and make normal free T4 misleading?

Standard thyroid assessments that rely primarily on free thyroxine (FT4) and TSH often overlook peripheral tissue-level thyroid hormone activity, which is heavily regulated by enzymatic deiodination.

Genetic modulation of thyroid metabolites

• The DIO1 rs2235544 single nucleotide polymorphism (SNP) directly dictates the efficiency of peripheral T4-to-T3 conversion and circulating metabolite profiles.
• The minor C allele is linked to enhanced type 1 deiodinase (D1) function, resulting in a higher free T3 to free T4 (FT3/FT4) ratio, elevated FT3, and lower reverse T3 (rT3).
• Conversely, the major A allele reduces conversion kinetics; individuals homozygous for the A allele (AA) exhibit a lower FT3/FT4 ratio, lower active FT3, and elevated rT3 due to impaired clearance and conversion.

Mechanistic limits of relying on free T4

• Circulating FT4 acts as a prohormone reservoir and does not reliably reflect intracellular or systemic active T3 availability when deiodination is compromised.
• The common DIO2 Thr92Ala (rs225014) polymorphism reduces type 2 deiodinase catalytic activity, lowering localized T3 conversion even when TSH and FT4 appear normalized on standard levothyroxine therapy.
• Because deiodinases are selenoproteins, selenium deficiency directly impairs both DIO1 and DIO2 function, decoupling active T3 levels from normal FT4 concentrations. Systemic stressors and non-thyroidal illness syndrome (NTIS) similarly suppress peripheral conversion, leading to a low T3 state despite normal FT4.

Bottom line

• Normal serum FT4 levels alone are insufficient to confirm adequate active T3 availability, as genetic variations in DIO1 (rs2235544) and DIO2 (Thr92Ala), alongside selenium deficiency and systemic illness, significantly impair peripheral conversion and tissue-level thyroid status.